Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + zuberitamab + cyclophosphamide + doxorubicin + prednisone + orelabrutinib
- Development stage
- Phase 2
- Lead developer
- Innocare
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
POLA-Hi-CHP + orelabrutinib is an investigational chemoimmunotherapy combination regimen being evaluated for the treatment of the MCD subtype of diffuse large B-cell lymphoma (DLBCL). The regimen consists of the antibody-drug conjugate **polatuzumab vedotin** (targeting CD79b), the anti-CD20 monoclonal antibody **zuberitamab**, the chemotherapy agents **cyclophosphamide** and **doxorubicin**, the corticosteroid **prednisone**, and the small-molecule Bruton's tyrosine kinase (BTK) inhibitor **orelabrutinib**. This combination targets multiple pathways in B-cell malignancies, including B-cell receptor signaling and direct cytotoxic effects. It is specifically studied in the MCD subtype (defined by MYD88 and CD79B mutations), which often shows sensitivity to BTK inhibition. The regimen is typically administered as induction therapy followed by orelabrutinib monotherapy maintenance.
- Brand names
- AnshidaObritinib
- Other names
- VepoliximabPola-Hi-CHP-OPola-Hi-CHP plus orelabrutinib
02
Targets
BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainDNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on polatuzumab vedotin + zuberitamab + cyclophosphamide + doxorubicin + prednisone + orelabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + zuberitamab + cyclophosphamide + doxorubicin + prednisone + orelabrutinib.